companies that make glp-1 drugs Comparing Ozempic, Wegovy and Other 2025’s Breakthrough GLP-1 Obesity Treatments:
Description
According to GoodRx, 88% of patients who still have coverage for GLP-1 agonists will face additional requirements to access them
Product and regulatory tracking focused on FDA and EMA approvals, cardiovascular outcomes trial readouts, and combination product development for weight management
November 21, 2019
Notably, exenatide immediate-release (Byetta) and lixisenatide (Adlyxin, and in Soliqua) do not carry this boxed warning or contraindication
But with speed comes risk
